In the ongoing human effort to outpace chronic disease, a large real-world study of nearly 58,000 adults has offered a measured verdict on two widely used weight-loss medications: semaglutide appears modestly superior to liraglutide in preventing the onset of diabetes, though only after six months of sustained use. The finding, drawn from insurance records spanning 2018 to 2023, reflects both the promise and the patience required by modern pharmacology — answers that reveal themselves slowly, and only partially. The heart, for now, keeps its secrets, as too few cardiovascular events occurred t
Semaglutide Shows Lower Diabetes Risk Than Liraglutide in Real-World Study
The advantage only became visible once people had been on it long enough.
Mark
Why does the diabetes advantage only show up after six months? Is something changing in how the drug works?
Mimi
The researchers can't say for certain. It could be that semaglutide takes time to exert its full effect, or that people who stick with it longer experience greater benefit. But the study design doesn't let them distinguish between those possibilities. They're watching what happens in the real world, not controlling the conditions.
Mark
So the cardiovascular findings are basically a wash.
Mimi
Essentially, yes. Only 57 events in 57,456 people over a year. That's actually a sign of health in the population—these are people without prior heart disease—but it means the study was underpowered to detect differences. You'd need either more people, longer follow-up, or a higher-risk population to see cardiovascular effects clearly.
Mark
The switching is striking. A third of liraglutide users switched to semaglutide.
Mimi
It suggests people were voting with their feet. Maybe semaglutide worked better for them, or had fewer side effects, or they heard it was more effective. The researchers counted people by their starting drug, so those switches don't change the analysis. But they do reflect real preferences.
Mark
Does this study change clinical practice?
Mimi
Probably not dramatically. Doctors already knew both drugs work. This adds evidence that semaglutide might have a slight edge for diabetes prevention, but the difference is modest—12 percent. For cardiovascular protection, which is often the bigger concern, we still don't have a clear answer.
Mark
What would a better study look like?
Mimi
Longer follow-up, ideally several years. A population at higher cardiovascular risk, so you'd actually see enough events to measure. And ideally, weight and blood sugar measurements, not just claims data. You'd want to know whether the drugs are working through weight loss or through other mechanisms.
The Pulse
- Semaglutide pulled ahead of liraglutide in diabetes prevention, but only after six months — the advantage is real, yet it demands time to surface.
- Just 57 cardiovascular events across nearly 58,000 participants left researchers unable to determine which drug better protects the heart, a silence that carries its own urgency.
- Dropout rates were striking: nearly 80 percent of liraglutide users and more than half of semaglutide users stopped their medication during the study, exposing the fragile relationship between patients and these demanding, expensive treatments.
- Researchers are calling for longer follow-up periods and larger cardiovascular datasets — the current evidence is a beginning, not a conclusion.
In the ongoing human effort to outpace chronic disease, a large real-world study of nearly 58,000 adults has offered a measured verdict on two widely used weight-loss medications: semaglutide appears modestly superior to liraglutide in preventing the onset of diabetes, though only after six months of sustained use. The finding, drawn from insurance records spanning 2018 to 2023, reflects both the promise and the patience required by modern pharmacology — answers that reveal themselves slowly, and only partially. The heart, for now, keeps its secrets, as too few cardiovascular events occurred to permit any reliable comparison between the two drugs.
Nearly 58,000 adults taking injectable weight-loss medications became the subjects of an unusual real-world comparison. Researchers drew on insurance claims from 2018 to 2023 to examine what happened when people took semaglutide versus liraglutide — two drugs from the same medication family, both approved for chronic weight management. Excluding anyone who already had diabetes or heart disease, they carefully matched participants and ended up with 57,456 people, evenly split, with an average age of 45 and roughly 83 percent women.
The story that emerged unfolded in stages. In the first six months, the two drugs appeared roughly equivalent at preventing diabetes. But beyond that threshold, semaglutide users developed diabetes at a rate about 12 percent lower than those on liraglutide — a meaningful difference that only became visible with time. Across the full study period, 1,104 people developed diabetes between the two groups.
The cardiovascular picture proved far murkier. Only 57 people experienced a heart attack, stroke, or heart failure across the entire population — a number too small to support any reliable comparison. Even when researchers broadened their definition of cardiovascular events, the statistical power remained insufficient. The scale, as it were, had too few data points to register a difference.
The study also laid bare how difficult these medications are to sustain. Nearly 80 percent of liraglutide users discontinued, as did more than half of semaglutide users — a real-world messiness shaped by cost, injection burden, and tolerability. Researchers counted participants according to the drug they started on, regardless of adherence, but the dropout rates hint at the practical limits of these treatments.
Important gaps remain: the insurance claims data contained no weight, BMI, or blood sugar measurements, the follow-up period averaged just one year, and the population skewed female and insured. What this large comparison ultimately offers is a partial answer — semaglutide holds a modest edge in diabetes prevention, while the question of cardiovascular protection waits for longer studies and more time.
Nearly 58,000 adults taking weight-loss medications became the subjects of an unusual experiment: researchers watched what happened when they took one drug instead of another, and then tried to figure out which one worked better. The answer, it turned out, was more complicated than a simple yes or no.
The study, published in the British Journal of Clinical Pharmacology, compared semaglutide and liraglutide—two injectable drugs from the same family of medications, both approved for chronic weight management. Researchers pulled data from insurance claims between 2018 and 2023, identifying adults who had started one drug or the other. They excluded anyone who already had diabetes or heart disease, since the question they wanted to answer was whether these medications could prevent those conditions from developing in the first place. After careful matching—pairing each person on liraglutide with someone similar on semaglutide—they ended up with 57,456 people, evenly split between the two drugs. The average age was 45. About 83 percent were women. Roughly 40 percent had high blood pressure.
What happened over the next year told a story that unfolded in stages. When researchers looked at the first six months, the two drugs appeared roughly equivalent in preventing diabetes. But something shifted after that. Beyond six months, semaglutide users developed diabetes at a measurably lower rate than liraglutide users—about 12 percent lower, after accounting for age and other health factors. It was a meaningful difference, but it only became visible once people had been on the medication long enough. During the entire follow-up period, 1,104 people developed diabetes across both groups. The finding suggests that semaglutide's advantage isn't immediate; it accumulates over time.
The cardiovascular picture, however, remained stubbornly unclear. Only 57 people in the entire study experienced a heart attack, stroke, or heart failure. That's a remarkably small number given the size of the population, and it meant researchers couldn't reliably compare how well each drug protected the heart. They found 30 heart attacks, 21 strokes, and 6 cases of heart failure. The numbers were too sparse to draw firm conclusions. When they looked at a broader definition of cardiovascular problems—adding in unstable angina and procedures to open blocked arteries—they still couldn't detect a meaningful difference between the drugs. The confidence intervals were wide, the statistical power insufficient. It was like trying to measure the difference between two objects when your scale only has a few data points.
One thing the data made abundantly clear was how hard it is to keep people on these medications. More than half of those taking semaglutide stopped the drug during the study period, and nearly 80 percent of liraglutide users discontinued. Some switched to the other drug—6 percent of semaglutide users moved to liraglutide, while 33 percent of liraglutide users switched the other direction. This real-world messiness is precisely why the researchers designed their analysis the way they did: they counted people according to which drug they started on, regardless of whether they stuck with it. But it also hints at a practical reality—these medications are expensive, they require weekly or daily injections, and many people find them difficult to tolerate long-term.
The study had other limitations worth noting. The researchers were working with insurance claims data, which doesn't include weight, body mass index, or blood sugar measurements—the very metrics that matter most when evaluating weight-loss drugs. The follow-up period was relatively short, just a median of one year. The population was predominantly female and insured, which means the findings may not apply equally to men or to uninsured people. And because this was observational research rather than a randomized trial, unmeasured differences between the groups could have influenced the results.
What emerges from this large, real-world comparison is a partial answer: semaglutide appears modestly better at preventing diabetes, at least beyond the first six months of treatment. But whether it's better at preventing heart disease remains unknown. That question will require longer studies, more cardiovascular events, and perhaps a different approach to measuring outcomes. For now, the two drugs remain broadly similar in their effects, with semaglutide holding a slight edge on the metric that was most clearly measurable.
Notable Quotes
The association favoring semaglutide emerged later in follow-up, although it does not establish an effect of continuous treatment duration.— Study researchers
Want the full story?
Read the original at News-Medical ↗
Health & Medicine